Abstract
Objectives : We investigated the detection rate and genotypes of HR-HPV in endocervical cytology specimens to examine the importance of HR-HPV detection and HR-HPV genotyping in cervical cancer screening.
Study Design : The study population was composed of women being followed up by periodic checkups for SIL and those undergoing secondary health examinations ; the women from both subgroups were aged ≥20 years. Cases with ASC-US or more severe abnormalities on BD SurePathTM were subjected to genotyping for HR-HPV and underwent cervical biopsy.
Results : Of the 134 subjects examined, 108 (80.6%) were found to be positive for HR-HPV. There were 86 subjects in whom the HR-HPV types could be identified, with types 16, 52 and 58 accounting for ≥10% of cases each, and for 48.8% (42/86) overall. Of the subjects with CIN 2 or more severe lesions, 82.6% (38/46) were found to be positive for any of the HR-HPV types 16, 52 and 58, with this percentage increasing to 95.7% (44/46) when types 18, 31 and 33 were also included. The HR-HPV positive rates in cases with CIN 2 or more and<CIN 2 lesions were 92.3% (48/52) and 68.0% (34/54), respectively.
Conclusion : HR-HPV types 16, 52, 58, 18, 31 and 33 were common in subjects with CIN 2 or more severe lesions. Therefore, particular care is required in the management of cases where any of these HR-HPV types is identified in the presence of ASC-US or more severe abnormalities.
